Glutathione and N-acetylcysteine in TB management.

IF 3.4 3区医学 Q2 INFECTIOUS DISEASES

International Journal of Tuberculosis and Lung Disease Pub Date : 2025-03-31 DOI:10.5588/ijtld.24.0604

M J Nasiri, N Khoshdel, V Venketaraman

{"title":"Glutathione and N-acetylcysteine in TB management.","authors":"M J Nasiri, N Khoshdel, V Venketaraman","doi":"10.5588/ijtld.24.0604","DOIUrl":null,"url":null,"abstract":"<sec><title>BACKGROUND</title>TB remains a major global health challenge. Glutathione (GSH) and N-acetylcysteine (NAC) have been proposed as adjunctive therapies with potential clinical and immunomodulatory benefits. This systematic review aims to evaluate the efficacy, safety, and immunomodulatory effects of GSH and NAC as adjunctive therapies in TB management.</sec><sec><title>METHODS</title>PubMed/MEDLINE, Embase, and Cochrane CENTRAL were searched until October 15, 2024. We included studies assessing the efficacy of GSH and NAC in TB management, focusing on clinical outcomes such as lung function recovery, sputum conversion, hepatoprotection, and immune response modulation. The quality of the studies was assessed using the Cochrane Risk of Bias tool.</sec><sec><title>RESULTS</title>Eight controlled trials were included. GSH and NAC significantly improved lung function accelerated sputum conversion, and provided hepatoprotective effects. GSH, particularly in its liposomal form, enhanced immune responses by modulating cytokine levels and reducing oxidative stress. Most adverse effects reported were mild and manageable, indicating a favourable safety profile for both agents.</sec><sec><title>CONCLUSIONS</title>GSH and NAC show promise as adjunctive therapies in TB management, demonstrating improvements in lung function, sputum conversion, and hepatoprotection while also enhancing immune responses.</sec>.","PeriodicalId":14411,"journal":{"name":"International Journal of Tuberculosis and Lung Disease","volume":"29 4","pages":"171-177"},"PeriodicalIF":3.4000,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Tuberculosis and Lung Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5588/ijtld.24.0604","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

BACKGROUNDTB remains a major global health challenge. Glutathione (GSH) and N-acetylcysteine (NAC) have been proposed as adjunctive therapies with potential clinical and immunomodulatory benefits. This systematic review aims to evaluate the efficacy, safety, and immunomodulatory effects of GSH and NAC as adjunctive therapies in TB management.METHODSPubMed/MEDLINE, Embase, and Cochrane CENTRAL were searched until October 15, 2024. We included studies assessing the efficacy of GSH and NAC in TB management, focusing on clinical outcomes such as lung function recovery, sputum conversion, hepatoprotection, and immune response modulation. The quality of the studies was assessed using the Cochrane Risk of Bias tool.RESULTSEight controlled trials were included. GSH and NAC significantly improved lung function accelerated sputum conversion, and provided hepatoprotective effects. GSH, particularly in its liposomal form, enhanced immune responses by modulating cytokine levels and reducing oxidative stress. Most adverse effects reported were mild and manageable, indicating a favourable safety profile for both agents.CONCLUSIONSGSH and NAC show promise as adjunctive therapies in TB management, demonstrating improvements in lung function, sputum conversion, and hepatoprotection while also enhancing immune responses..

查看原文本刊更多论文

谷胱甘肽和n -乙酰半胱氨酸在结核病管理中的作用。

背景：结核病仍然是一项重大的全球卫生挑战。谷胱甘肽（GSH）和n -乙酰半胱氨酸（NAC）已被认为是具有潜在临床和免疫调节益处的辅助疗法。本系统综述旨在评估GSH和NAC作为结核病辅助治疗的有效性、安全性和免疫调节作用。方法检索spubmed /MEDLINE、Embase和Cochrane CENTRAL至2024年10月15日。我们纳入了评估GSH和NAC在结核病治疗中的疗效的研究，重点关注临床结果，如肺功能恢复、痰转化、肝保护和免疫反应调节。使用Cochrane偏倚风险工具评估研究的质量。结果纳入8项对照试验。GSH和NAC可显著改善肺功能，加速痰转化，并具有保肝作用。谷胱甘肽，特别是其脂质体形式，通过调节细胞因子水平和减少氧化应激来增强免疫反应。报告的大多数不良反应是轻微和可控的，表明两种药物的良好安全性。结论：sgsh和NAC作为结核病治疗的辅助疗法，显示出改善肺功能、痰转化和肝保护的潜力，同时也增强了免疫反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Tuberculosis and Lung Disease 医学-传染病学

CiteScore

4.90

自引率

20.00%

发文量

266

审稿时长

2 months

期刊介绍： The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.